Sprifermin

Sprifermin (INN) (developmental code name AS-902330), also known as recombinant human fibroblast growth factor 18 (rhFGF18), is a recombinant form of human fibroblast growth factor 18 (FGF18) which is under development by Merck and Nordic Bioscience for the treatment of osteoarthritis. As a recombinant form of FGF18, sprifermin is a potent agonist of the FGFR2 and FGFR3. 
As of 2017, the drug is in phase II clinical trials for the treatment of osteoarthritis.
2019 outcomes of phase 2 clinical trial for KOA, shows improvement in cartilage thickness, but fails to satisfy tests like the WOMAC, therefore failing to satisfy its primary end points.
However in some subgroups where cartilage thickness is of specific concern, clinical significance might be achieved.